NanoViricides NNVC 深 沪
已收盘 12-12 16:00:00 美东时间
1.25
-0.050
-3.85%
华盛通- 最 高1.30
- 今 开1.30
- 成交量 31.72万股
- 最 低 1.25
- 昨 收 1.30
- 总市值 2009.00万
- 52周最高 2.2299
- 市盈率 静 --
- 换手率 1.97%
- 52周最低 0.94
- 委 比 33.33%
- 总股本 1607.20万
- 历史最高 151.80
- 量 比 0.64
- 振 幅 3.85%
- 历史最低 0.94
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NanoViricides Signs Master Services Agreement With Only Orphans Cote To Advance Orphan Drug Strategy For NV-387
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology
12-01 21:35
NanoViricides Secures $6 Million Through Securities Offering
An update from NanoViricides ( ($NNVC) ) is now available. On November 10, 2025...
11-15 06:13
NanoViricides Receives DRC Approval To Start Phase II Trial Of NV-387 For MPox Treatment
NanoViricides, Inc. (NYSE:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic
11-10 21:35
NANO Nuclear Energy Celebrates KRONOS MMR™ Event at The University of Illinois Highlighted by Prospective Customer Announcing Planned Feasibility Study for 15 KRONOS Micro Modular Reactors
NANO Nuclear Energy Inc. celebrated the start of site-characterization drilling for its KRONOS MMR™ prototype project at the University of Illinois Urbana-Champaign, with support from key stakeholders including BaRupOn LLC, which announced a feasibility study for 15 reactors. The eventfeatured remarks from NANO's senior management, U. of I. leadership, and representatives from engineering, construction, and commercial stakeholders, highlighting s...
10-29 12:00
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Nanobiotix announced the completion of transferring sponsorship and operational control of the NANORAY-312 clinical trial for JNJ-1900 (NBTXR3) to Johnson & Johnson. Interim data analysis is expected in 1H2027 after recruitment and requisite events. Nanobiotix will continue to provide updates on its sponsored studies and collaborations. JNJ-1900, a novel oncology product, is activated by radiotherapy and has shown potential in treating solid tumo...
10-24 06:00
NANO Nuclear Finalizes Acquisition of Global First Power from USNC, Strengthening its Position as a North American Leader in Nuclear Microreactor Development
NANO Nuclear Energy收购Global First Power（加拿大），获得了在Ontario建造KRONOS MMR™示范项目的加拿大核安全委员会许可申请，加强其在北美微型核反应堆开发的领先地位。NANO正在Canada和美国同步推进许可和建设项目，计划通过收购后的监管和施工进展加速商业化部署。
10-22 12:00
NANO Nuclear Included in Morgan Stanley’s National Security Index
New York, N.Y., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) has been included in Morgan Stanley’s National Security Index (MSXXNSEC), recognizing its advanced nuclear microreactor technologies aimed at strengthening U.S. energy sovereignty and national security. NANO Nuclear’s inclusion highlights its role in developing critical energy technologies, such as its KRONOS MMR™ Micro Modular Reactor Energy System. The comp...
10-20 12:00
NANO Nuclear Energy Announces its Participation in Several Upcoming Investor Focused Conferences
NANO Nuclear Energy Inc. (NASDAQ: NNE), an advanced nuclear energy company, announced its participation in upcoming investor events, including the Spartan Capital Investor Conference 2025, Bank of America Clean Tech Symposium 2025, Benchmark’s 14th Annual Discovery One-on-One Conference, B. Riley Securities’ Convergence Conference, and Northland Capital Markets Growth Conference. The company develops clean energy solutions across five business li...
10-16 12:30
NANO Nuclear Energy Announces Milestone Ceremony to Begin Drilling Work with the University of Illinois for its Patented Flagship KRONOS MMR™ Micro Modular Reactor Energy System
NANO Nuclear Energy Inc. announced a milestone event on October 24, 2025, at the University of Illinois Urbana-Champaign to showcase progress on its KRONOS MMR™ microreactor prototype. The event will highlight site characterization and drilling activities by AECOM, serving as a关键 step toward submitting a construction permit application in early 2026. The KRONOS MMR™, a high-temperature gas-cooled microreactor, aims to provide carbon-free power fo...
10-14 12:00
NANO Nuclear Energy Announces $400 Million Oversubscribed Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
NANO Nuclear Energy Inc. has announced a $400 million oversubscribed private placement of common stock under Nasdaq rules. The offering, led by institutional investors, is expected to close by October 10, 2025. Proceeds will support the KRONOS MMR Energy System development, other microreactor projects, strategic acquisitions, and general corporate purposes. The company's cash position is expected to reach approximately $600 million post-closing.
10-08 03:36
